Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Melanotan-1 Legal 2026 Status: International Jurisdiction Comparison

United States (FDA) Yes. Institutional buyers with documentation only Prohibited. Classified as unapproved drug Customs screens all peptide imports; residential shipments flagged for inspection Research procurement is straightforward for accredited labs, but c

This comparison does not assign a generated winner or score.

  • United States (FDA)
  • Yes. Institutional buyers with documentation only
  • Prohibited. Classified as unapproved drug
  • Customs screens all peptide imports; residential shipments flagged for inspection
  • Research procurement is straightforward for accredited labs, but consumer pathways remain completely closed. No softening in 2026 enforcement.
  • European Union (EMA)
  • Yes. Labs registered under national research frameworks
  • Prohibited. No cosmetic or OTC approval
  • Variable by member state; Germany and France enforce strict peptide import controls
  • Regulatory alignment with FDA: research access exists, consumer marketing does not. Enforcement inconsistent across borders.
  • United Kingdom (MHRA)
  • Yes. Licensed research facilities only
  • Prohibited under Cosmetic Products Enforcement Regulations 2013
  • Post-Brexit customs require detailed peptide documentation; residential imports routinely seized
  • MHRA treats melanotan-1 identically to melanotan-2: banned for cosmetic use, restricted to documented research.
  • Australia (TGA)
  • Yes. Schedule 4 (Prescription Only) for approved research
  • Prohibited. No approved therapeutic use
  • TGA Border Force actively intercepts peptide imports; high seizure rate for undeclared parcels
  • Strictest enforcement in this comparison. Even research use requires TGA import permit.
  • Canada (Health Canada)
  • Yes. Research exemption under Food and Drug Regulations
  • Prohibited. No DIN (Drug Identification Number) issued
  • CBSA inspects peptide shipments; mislabeled 'supplements' flagged and destroyed
  • Regulatory stance mirrors FDA closely. Research access exists but consumer channels face active enforcement.
More references

Related material